Current status of radioligand antibodies in the treatment of malignancy.
Monoclonal anti-tumor antibodies labeled with a radioactive moiety present an exciting new approach to cancer therapy. With the advent of hybridoma technology, monoclonal antibodies can now be produced in quantity. Indeed, antibodies against tumor-related and tumor-specific antigens have been produced, labeled with a radioactive substance, and used therapeutically. The rationale for this therapeutic approach and the results of human clinical trials will be reported herein.
Maners
A W
AW
Division of Radiation Therapy, University of Arkansas for Medical Sciences, Little Rock 72205.
Sanders
M M
MM
Pappas
A A
AA
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000276:immunology; D000912:Antibodies, Neoplasm; D000918:Antibody Specificity; D006801:Humans; D006825:Hybridomas; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D009369:Neoplasms / Q000532:radiotherapy*
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D007457:Iodine Radioisotopes